Literature DB >> 2689038

Therapeutic monitoring of theophylline. Rationale and current status.

C W Bierman1, P V Williams.   

Abstract

Theophylline has been demonstrated to be a useful agent in the therapy of chronic asthma. Its use must be tempered with knowledge of its adverse effects and that these effects are related primarily to serum concentration. Accordingly, it is mandatory to monitor serum theophylline concentrations on a regular basis with any patient receiving maintenance therapy with theophylline. It is also necessary to recognise the potential side effects of theophylline therapy, and when such a patient displays symptoms of vomiting, headache or seizures, serum theophylline concentration must be checked even if a recent concentration was within the therapeutic range. The means for monitoring theophylline concentrations are now available even to the average physician who does not have immediate access to a laboratory that can provide timely serum theophylline determinations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2689038     DOI: 10.2165/00003088-198917060-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  30 in total

1.  The influence of cigarette smoking and sex on theophylline disposition.

Authors:  J R Powell; J F Thiercelin; S Vozeh; L Sansom; S Riegelman
Journal:  Am Rev Respir Dis       Date:  1977-07

2.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

3.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

4.  The relation of product formulation to absorption of oral theophylline.

Authors:  M Weinberger; L Hendeles; L Bighley
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

5.  Double-blind trial of aminophylline in status asthmaticus.

Authors:  W E Pierson; C W Bierman; S J Stamm; P P Van Arsdel
Journal:  Pediatrics       Date:  1971-10       Impact factor: 7.124

Review 6.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

7.  A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma.

Authors:  C T Furukawa; G G Shapiro; C W Bierman; M J Kraemer; D J Ward; W E Pierson
Journal:  Pediatrics       Date:  1984-10       Impact factor: 7.124

8.  Nonlinear theophylline elimination.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

9.  Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study.

Authors:  M R Alexander; W L Dull; J E Kasik
Journal:  JAMA       Date:  1980-11-21       Impact factor: 56.272

10.  Cognitive and behavioral findings in children taking theophylline.

Authors:  C T Furukawa; T R DuHamel; L Weimer; G G Shapiro; W E Pierson; C W Bierman
Journal:  J Allergy Clin Immunol       Date:  1988-01       Impact factor: 10.793

View more
  7 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

2.  Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.

Authors:  J Sato; H Nakata; E Owada; T Kikuta; M Umetsu; K Ito
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  To study the efficacy and safety of doxophylline and theophylline in bronchial asthma.

Authors:  Sami Manzoor Margay; Samina Farhat; Sharanjit Kaur; Hilal Ahmad Teli
Journal:  J Clin Diagn Res       Date:  2015-04-01

Review 4.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 5.  Influence of drug formulation on drug concentration-effect relationships.

Authors:  G Castañeda-Hernández; G Caillé; P du Souich
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

Review 7.  Doxofylline: The next generation methylxanthine.

Authors:  Jhuma Sankar; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2008-03       Impact factor: 1.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.